Pan Yuting, Li Weihao, Feng Ying, Xu Jing, Cao Huifang
Department of Respiratory Medicine, Shanghai Medical College of Fudan University, Xuhui, Shanghai 200032, P.R. China.
Department of Respiratory Diseases, Jing'an District Centre Hospital of Fudan University, Shanghai 200040, P.R. China.
Exp Ther Med. 2020 Feb;19(2):1407-1416. doi: 10.3892/etm.2019.8351. Epub 2019 Dec 19.
Asthma is a chronic disease that threatens public health worldwide. Multiple studies have shown that oxidative stress plays an important role in the pathogenesis of asthma. Edaravone (Eda), a free radical scavenger, has been found to have a protective effect against lung injury due to its ability to eliminate reactive oxygen species. The present study aimed to investigate the effect of Eda on asthma and the mechanism underlying its actions. An experimental asthma model was induced in mice, before they were treated with different doses of Eda. Measurements of airway responsiveness to methacholine (Mch), cell counts and cytokine levels in bronchoalveolar lavage fluid (BALF) and of the oxidative products and antioxidant enzymes in lung tissue were taken in these asthma model mice and compared with control mice. Protein levels of kelch-like ECH-associated protein-1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) and hemeoxygenase-1 (HO-1) were determined in the lung tissue of normal mice and Nrf2 and HO-1-deficient mice subject to the asthma model to investigate the mechanisms underlying Eda action. The results indicated that Eda effectively reduced airway responsiveness to Mch. The total number of cells and the numbers of eosinophils, lymphocytes and neutrophils in BALF of asthma model mice were also significantly reduced by Eda treatment when compared with normal saline treatment. Eda treatment significantly alleviated perivascular edema, peribronchial inflammation and macrophage infiltration in the alveolar space and decreased the levels of inflammatory cytokines released in BALF compared with control. Eda also significantly reduced the levels of oxidative stress markers in BALF and restored the levels of antioxidative enzyme, superoxide dismutase, when compared with control. The Keap1/Nrf2 ratio was significantly decreased with Eda compared with control due to an increase in Nrf2 and a decrease in Keap1 expression. HO-1 expression was increased by Eda. The airway responsiveness of Nrf2 mice or HO-1 mice to Mch was significantly higher compared with normal mice treated with Eda. Taken together, the results of the present study show that Eda exerts anti-inflammatory and antioxidative effects, which suggests a potential use for Eda in reduction of asthma severity. The activated Keap1/Nrf2 pathway and HO-1 may be involved in the anti-asthmatic effect of Eda.
哮喘是一种威胁全球公众健康的慢性疾病。多项研究表明,氧化应激在哮喘发病机制中起重要作用。依达拉奉(Eda)是一种自由基清除剂,因其具有清除活性氧的能力,已被发现对肺损伤具有保护作用。本研究旨在探讨依达拉奉对哮喘的影响及其作用机制。在对小鼠进行不同剂量的依达拉奉治疗之前,先诱导建立实验性哮喘模型。对这些哮喘模型小鼠进行气道对乙酰甲胆碱(Mch)的反应性测量、支气管肺泡灌洗液(BALF)中的细胞计数和细胞因子水平测量,以及肺组织中氧化产物和抗氧化酶的测量,并与对照小鼠进行比较。在正常小鼠以及接受哮喘模型的Nrf2和HO-1基因缺陷小鼠的肺组织中测定kelch样ECH相关蛋白-1(Keap1)/核因子红细胞2相关因子2(Nrf2)和血红素加氧酶-1(HO-1)的蛋白水平,以研究依达拉奉作用的潜在机制。结果表明,依达拉奉有效降低了气道对乙酰甲胆碱的反应性。与生理盐水处理相比,依达拉奉处理还显著降低了哮喘模型小鼠BALF中的细胞总数以及嗜酸性粒细胞、淋巴细胞和中性粒细胞的数量。与对照组相比,依达拉奉处理显著减轻了血管周围水肿、支气管周围炎症和肺泡腔内巨噬细胞浸润,并降低了BALF中释放的炎症细胞因子水平。与对照组相比,依达拉奉还显著降低了BALF中氧化应激标志物的水平,并恢复了抗氧化酶超氧化物歧化酶的水平。与对照组相比,依达拉奉使Keap1/Nrf2比值显著降低,原因是Nrf2表达增加而Keap1表达减少。依达拉奉使HO-1表达增加。与接受依达拉奉治疗的正常小鼠相比,Nrf2基因缺陷小鼠或HO-1基因缺陷小鼠对乙酰甲胆碱的气道反应性显著更高。综上所述,本研究结果表明依达拉奉具有抗炎和抗氧化作用,这提示依达拉奉在减轻哮喘严重程度方面具有潜在用途。激活的Keap1/Nrf2途径和HO-1可能参与了依达拉奉的抗哮喘作用。